Structure and ligand recognition of class C GPCRs

Acta Pharmacologica Sinica

Volumn 33, Issue 3, 2012, Pages 312-323

  Chun, Lei ^a   Zhang, Wen Hua ^a   Liu, Jian Feng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

allosteric modulators; allosteric sites; G protein coupled receptors (GPCRs); ligands; orthosteric sites; structure

Indexed keywords

CELL SURFACE RECEPTOR; G PROTEIN COUPLED RECEPTOR;

DRUG TARGETING; HUMAN; LIGAND BINDING; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW;

ALLOSTERIC SITE; ANIMALS; HUMANS; LIGANDS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84863255255     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.186     Document Type: Review

References (98)

1. George SR, O'Dowd BF, Lee SP. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov 2002; 1: 808-20. (Pubitemid 37361564)
2. Lagerstrom MC, Schioth HB. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 2008; 7: 339-57.
3. Pin JP, Galvez T, Prezeau L. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther 2003; 98: 325-54. (Pubitemid 36638547)
4. Rondard P, Goudet C, Kniazeff J, Pin JP, Prezeau L. The complexity of their activation mechanism opens new possiblities for the modulation of mGlu and GABAB class C G protein-coupled receptors. Neuropharmacology 2011; 60: 82-92.
5. Urwyler S. Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives. Pharmacol Rev 2011; 63: 59-126.
6. Kniazeff J, Prezeau L, Rondard P, Pin JP, Goudet C. Dimers and beyond: The functional puzzles of class C GPCRs. Pharmacol Ther 2011; 130: 9-25.
7. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 2009; 8: 41-54.
8. Conn PJ, Pin J-P. Pharmacology and functions of metabotropic glutamate receptors. Annue Rev Pharmacol Toxicol 1997; 37: 205-37. (Pubitemid 27238875)
9. Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annue Rev Pharmacol Toxicol 2010; 50: 295-322.
10. Pin JP, Acher F. The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr Drug Targets CNS Neurol Disord 2002; 1: 297-317.
11. Johnson KA, Conn PJ, Niswender CM. Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol Disord Drug Targets 2009; 8: 475-91.
12. Dolen G, Carpenter RL, Ocain TD, Bear MF. Mechanism-based approaches to treating fragile X. Pharmacol Ther 2010; 127: 78-93.
13. Marino MJ, Williams DL Jr, O'Brien JA, Valenti O, McDonald TP, Clements MK, et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to parkinson's disease treatment. Proc Natl Acad Sci U S A 2003; 100: 13668-73. (Pubitemid 37444797)
14. Conn PJ, Lindsley CW, Jones CK. Activation of metabotropic gluatamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 2009; 30: 25-31.
15. Bettler B, Tiao JY. Molecular diversity, trafficking and subcellular localization of GABAB receptors. Pharmacol Ther 2006; 110: 533-43.
16. Jones KA, Borowsky B, Tamm JA, Craig DA, Durkin MM, Dai M, et al. GABAB receptors function as heteromeric assembly of the subunits GABABR1 and GABABR2. Nature 1998; 396: 674-79. (Pubitemid 29003945)
17. Kaupmann K, Malitschek B, Schuler V, Heid J, Froestl W, Beck P, et al. GABAB-receptor subtypes assemble into functional heteromeric complexes. Nature 1998; 396: 683-7. (Pubitemid 29003947)
18. Galvez T, Parmentier ML, Joly C, Malitschek B, Kaupmann K, Kuhn R, et al. Mutagenesis and modeling of the GABAB receptor extracellular domain support a Venus flytrap mechanism for ligand binding. J Biol Chem 1999; 274: 13362-9.
19. Margeta-Mitrovic M, Jan YN, Jan LY. Function of GB1 and GB2 subunits in G protein coupling of GABAB receptors. Proc Natl Acad Sci U S A 2001; 98: 14649-54. (Pubitemid 33121446)
20. Kuramoto N, Wilkins ME, Fairfax BP, Revilla-Sanchez R, Terunuma M, Tamaki K, et al. Phospho-dependent functional modulation of GABAB receptors by the metabolic sensor AMP-dependent protein kinase. Neuron 2007; 53: 233-47. (Pubitemid 46074400)
21. Dave KR, Lange-Asschenfeldt C, Raval AP, Prado R, Busto R, Saul I, et al. Ischemic preconditioning ameliorates excitotoxicity by shifting glutamate/gamma-aminobutyric acid release and biosynthesis. J Neurosci Res 2005; 82: 665-73. (Pubitemid 41740467)
22. Tu H, Xu C, Zhang W, Liu Q, Rondard P, Pin JP, et al. GABAB receptor activation protects neurons from apoptosis via IGF-1 receptor transactivation. J Neurosci 2010; 30: 749-59.
23. Goudet C, Magnaghi V, Landry M, Nagy F, Gereau RW 4th, Pin JP. Metabotropic receptors for glutamate and GABA in pain. Brain Res Rev 2009; 60: 43-56.
24. Cryan JF, Kaupmann K. Don't worry 'B' happy!: a role for GABAB receptors in anxiety and depression. Trends Pharmacol Sci 2005; 26: 36-43. (Pubitemid 40052708)
25. Bowery NG. GABAB receptor: a site of therapeutic benefit. Curr Opin Pharmacol 2006; 6: 37-43. (Pubitemid 43103818)
26. Brown EM. Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab 2007; 3: 122-33. (Pubitemid 46146965)
27. Deal C. Future therapeutic targets in osteoporosis. Curr Opin Rheumatol 2009; 21: 380-5.
28. Brown EM. Anti-parathyroid and anti-calcium sensing receptor antibodies in autoimmune hypoparathyroidism. Endocrinol Metab Clin North Am 2009; 38: 437-45.
29. Montmayeur JP, Liberles SD, Matsunami H, Buck LB. A candidate taste receptor gene near a sweet taste locus. Nat Neurosci 2001; 4: 492-8. (Pubitemid 32397186)
30. Nelson G, Hoon MA, Chandrashekar J, Zhang Y, Ryba NJ, Zuker CS. Mammalian sweet taste receptors. Cell 2001; 106: 381-90. (Pubitemid 32772621)
31. Zhang F, Klebansky B, Fine RM, Xu H, Pronin A, Liu H, et al. Molecular mechanism for the umami taste synergism. Proc Natl Acad Sci U S A 2008; 105: 20930-4.
32. Cao J, Huang S, Qian J, Huang J, Jin L, Su Z, et al. Evolution of the class C GPCR Venus flytrap modules involved positive selected functional divergence. BMC Evol Biol 2009; 9: 67.
33. Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, et al. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 2000; 407: 971-7.
34. Tsuchiya D, Kunishima N, Kamiya N, Jingami H, Morikawa K. Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd3+. Proc Natl Acad Sci U S A 2002; 99: 2660-5. (Pubitemid 34240517)
35. Bessis AS, Rondard P, Gaven F, Brabet I, Triballeau N, Prezeau L, et al. Closure of the Venus flytrap module of mGlu8 receptor and the activation process: Insights from mutations converting antagonists into agonists. Proc Natl Acad Sci U S A 2002; 99: 11097-102. (Pubitemid 34920885)
36. Kniazeff J, Saintot PP, Goudet C, Liu J, Charnet A, Guillon G, et al. Locking the dimeric GABAB G-protein-coupled receptor in its active state. J Neurosci 2004; 24: 370-7. (Pubitemid 38112368)
37. Tsuji Y, Shimada Y, Takeshita T, Kajimura N, Nomura S, Sekiyama N, et al. Cryptic dimer interface and domain organization of the extracellular region of metabotropic glutamate receptor subtype 1. J Biol Chem 2000; 275: 28144-51.
38. Romano C, Miller JK, Hyrc K, Dikranian S, Mennerick S, Takeuchi Y, et al. Covalent and noncovalent interactions mediate metabotropic glutamate receptor mGlu5 dimerization. Mol Pharmacol 2001; 59: 46-53. (Pubitemid 32043084)
39. Ray K, Hauschild BC, Steinbach PJ, Goldsmith PK, Hauache O, Spiegel AM. Identification of the cysteine residues in the amino-terminal extracellular domain of the human Ca2+ receptor critical for dimerization. Implications for function of monomeric Ca2+ receptor. J Biol Chem 1999; 274: 27642-50.
40. Ray K, Hauschild BC. Cys-140 is critical for metabotropic glutamate receptor-1 dimerization. J Biol Chem 2000; 275: 34245-51.
41. Liu J, Maurel D, Etzol S, Brabet I, Ansanay H, Pin JP, et al. Molecular determinants involved in the allosteric control of agonist affinity in the GABAB receptor by the GABAB2 subunit. J Biol Chem 2004; 279: 15824-30. (Pubitemid 38509269)
42. Rondard P, Huang S, Monnier C, Tu H, Blanchard B, Oueslati N, et al. Functioning of the dimeric GABAB receptor extracellular domain revealed by glycan wedge scanning. EMBO J 2008; 27: 1321-32. (Pubitemid 351655177)
43. Muto T, Tsuchiya D, Morikawa K, Jingami H. Structures of the extracellular regions of the group II/III metabotropic glutamate receptors. Proc Natl Acad Sci U S A 2007; 104: 3759-64. (Pubitemid 47189144)
44. Hu J, Hauache O, Spiegel AM. Human Ca2+ receptor cysteine-rich domain. Analysis of function of mutant and chimeric receptors. J Biol Chem 2000; 275: 16382-9. (Pubitemid 30366956)
45. Jiang P, Ji Q, Liu Z, Snyder LA, Benard LM, Margolskee RF, et al. The cysteine-rich region of T1R3 determines responses to intensely sweet proteins. J Biol Chem 2004; 279: 45068-75. (Pubitemid 39430921)
46. Rondard P, Liu J, Huang S, Malhaire F, Vol C, Pinault A, et al. Coupling of agonist binding to effector domain activation in metabotropic glutamate-like receptors. J Biol Chem 2006; 281: 24653-61. (Pubitemid 44274238)
47. Goudet C, Gaven F, Kniazeff J, Vol C, Liu J, Cohen-Gonsaud M, et al. Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors. Proc Natl Acad Sci U S A 2004; 101: 378-83. (Pubitemid 38084258)
48. Kniazeff J, Bessis AS, Maurel D, Ansanay H, Prezeau L, Pin JP. Closed state of both binding domains of homodimeric mGlu receptors is required for full activity. Nat Struct Mol Biol 2004; 11: 706-13. (Pubitemid 39014495)
49. Huang S, Cao J, Jiang M, Labesse G, Liu J, Pin JP, et al. Interdomain movements in metabotropic glutamate receptor activation. Proc Natl Acad Sci U S A 2011; 108: 15480-5.
50. Monnier C, Tu H, Bourrier E, Vol C, Lamarque L, Trinquet E, et al. Trans-activation between 7TM domains: implication in heterodimeric GABAB receptor activation. EMBO J 2011; 30: 32-42.
51. Brock C, Oueslati N, Soler S, Boudier L, Rondard P, Pin JP. Activation of a dimeric metabotropic glutamate receptor by intersubunit rearrangement. J Biol Chem 2007; 282: 33000-8. (Pubitemid 350161742)
52. Tateyama M, Abe H, Nakata H, Saito O, Kubo Y. Ligand-induced rearrangement of the dimeric metabotropic glutamate receptor 1alpha. Nat Struct Mol Biol 2004; 11: 637-42. (Pubitemid 38823530)
53. Tateyama M, Kubo Y. Dual signaling is differentially activated by different active states of the metabotropic glutamate receptor 1alpha. Proc Natl Acad Sci U S A 2006; 103: 1124-8. (Pubitemid 43212232)
54. Marcaggi P, Mutoh H, Dimitrov D, Beato M, Knopfel T. Optical measurement of mGluR1 conformational changes reveals fast activation, slow deactivation, and sensitization. Proc Natl Acad Sci U S A 2009; 106: 11388-93.
55. Pin JP, Joly C, Heinemann SF, Bockaert J. Domains involved in the specificity of G protein activation in phospholipase C-coupled metabotropic glutamate receptors. EMBO J 1994; 13: 342-8. (Pubitemid 24034216)
56. Bai M, Trivedi S, Brown EM. Dimerization of the extracellular calciumsensing receptor (CaR) on the cell surface of CaR-transfected HEK293 cells. J Biol Chem 1998; 273: 23605-10. (Pubitemid 28417555)
57. Yamashita T, Terakita A, Shichida Y. The second cytoplasmic loop of metabotropic glutamate receptor functions at the third loop position of rhodopsin. J Biochem 2001; 130: 149-55. (Pubitemid 32674576)
58. Frauli M, Hubert N, Schann S, Triballeau N, Bertrand HO, Acher F, et al. Amino-pyrrolidine tricarboxylic acids give new insight into group III metabotropic glutamate receptor activation mechanism. Mol Pharmacol 2007; 71: 704-12.
59. Brauner-Osborne H, Wellendorph P, Jensen AA. Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors. Curr Drug Targets 2007; 8: 169-84. (Pubitemid 46049458)
60. Hu J, Reyes-Cruz G, Chen W, Jacobson KA, Spiegel AM. Identification of acidic residues in the extracellular loops of the seven-transmembrane domain of the human Ca2+ receptor critical for response to Ca2+ and a positive allosteric modulator. J Biol Chem 2002; 277: 46622-31. (Pubitemid 35417662)
61. Petrel C, Kessler A, Maslah F, Dauban P, Dodd RH, Rognan D, et al. Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca2+-sensing receptor. J Biol Chem 2003; 278: 49487-94.
62. Petrel C, Kessler A, Dauban P, Dodd RH, Rognan D, Ruat M. Positive and negative allosteric modulators of the Ca2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J Biol Chem 2004; 279: 18990-7. (Pubitemid 38623329)
63. Hu J, McLarnon SJ, Mora S, Jiang J, Thomas C, Jacobson KA, et al. A region in the seven-transmembrane domain of the human Ca2+ receptor critical for response to Ca2+. J Biol Chem 2005; 280: 5113-20. (Pubitemid 40288687)
64. Pagano A, Ruegg D, Litschig S, Stoehr N, Stierlin C, Heinrich M, et al. The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J Biol Chem 2000; 275: 33750-8.
65. Malherbe P, Kratochwil N, Knoflach F, Zenner MT, Kew JN, Kratzeisen C, et al. Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J Biol Chem 2003; 278: 8340-7. (Pubitemid 36800582)
66. Malherbe P, Kratochwil N, Zenner MT, Piussi J, Diener C, Kratzeisen C, et al. Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)- pyridine. Mol Pharmacol 2003; 64: 823-32. (Pubitemid 37153050)
67. Zhang F, Klebansky B, Fine RM, Liu H, Xu H, Servant G, et al. Molecular mechanism of the sweet taste enhancers. Proc Natl Acad Sci U S A 2010; 107: 4752-7.
68. Triballeau N, Acher F, Brabet I, Pin JP, Bertrand HO. Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. J Med Chem 2005; 48: 2534-47. (Pubitemid 40520517)
69. Selvam C, Oueslati N, Lemasson IA, Brabet I, Rigault D, Courtiol T, et al. A virtual screening hit reveals new possibilities for developing group III metabotropic glutamate receptor agonists. J Med Chem 2010; 53: 2797-813.
70. Jiang P, Cui M, Zhao B, Snyder LA, Benard LM, Osman R, et al. Identification of the cyclamate interaction site within the transmembrane domain of the human sweet taste receptor subunit T1R3. J Biol Chem 2005; 280: 34296-305. (Pubitemid 41443155)
71. Jiang P, Cui M, Zhao B, Liu Z, Snyder LA, Benard LM, et al. Lactisole interacts with the transmembrane domains of human T1R3 to inhibit sweet taste. J Biol Chem 2005; 280: 15238-46. (Pubitemid 40562880)
72. Gregory KJ, Dong EN, Meiler J, Conn PJ. Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology 2011; 60: 66-81.
73. Muhlemann A, Ward NA, Kratochwil N, Diener C, Fischer C, Stucki A, et al. Determination of key amino acids implicated in the actions of allosteric modulation by 3,3'-difluorobenzaldazine on rat mGlu5 receptors. Eur J Pharmacol 2006; 529: 95-104.
74. Chen Y, Goudet C, Pin JP, Conn PJ. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro- 2H-isoindol-2-yl)methyl]phenyl}-2-hy droxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Mol Pharmacol 2008; 73: 909-18. (Pubitemid 351397895)
75. Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, et al. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol 1999; 55: 453-61. (Pubitemid 29128101)
76. Knoflach F, Mutel V, Jolidon S, Kew JN, Malherbe P, Vieira E, et al. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci U S A 2001; 98: 13402-7. (Pubitemid 33051375)
77. Hemstapat K, de Paulis T, Chen Y, Brady AE, Grover VK, Alagille D, et al. A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. Mol Pharmacol 2006; 70: 616-26. (Pubitemid 44092322)
78. Rowe BA, Schaffhauser H, Morales S, Lubbers LS, Bonnefous C, Kamenecka TM, et al. Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3-positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2-positive allosteric modulation site. J Pharmacol Exp Ther 2008; 326: 240-51. (Pubitemid 351872147)
79. Grillon C, Cordova J, Levine LR, Morgan CA 3rd. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl) 2003; 168: 446-54. (Pubitemid 36994028)
80. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007; 13: 1102-7. (Pubitemid 47517511)
81. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 2005; 4: 131-44. (Pubitemid 40277494)
82. Urwyler S, Mosbacher J, Lingenhoehl K, Heid J, Hofstetter K, Froestl W, et al. Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2- dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol 2001; 60: 963-71. (Pubitemid 33027431)
83. DeLapp NW. The antibody-capture [35S]GTPgammaS scintillation proximity assay: a powerful emerging technique for analysis of GPCR pharmacology. Trends Pharmacol Sci 2004; 25: 400-1.
84. Matsushita S, Nakata H, Kubo Y, Tateyama M. Ligand-induced rearrangements of the GABAB receptor revealed by fluorescence resonance energy transfer. J Biol Chem 2010; 285: 10291-9.
85. Binet V, Brajon C, Le Corre L, Acher F, Pin JP, Prezeau L. The heptahelical domain of GABAB2 is activated directly by CGP7930, a positive allosteric modulator of the GABAB receptor. J Biol Chem 2004; 279: 29085-91. (Pubitemid 38915779)
86. Tu H, Rondard P, Xu C, Bertaso F, Cao F, Zhang X, et al. Dominant role of GABAB2 and Gbetagamma for GABAB receptor-mediated-ERK1/2/ CREB pathway in cerebellar neurons. Cell Signal 2007; 19: 1996-2002. (Pubitemid 47086373)
87. Urwyler S, Pozza MF, Lingenhoehl K, Mosbacher J, Lampert C, Froestl W, et al. N,N′-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acidB receptor function. J Pharmacol Exp Ther 2003; 307: 322-30.
88. Malherbe P, Masciadri R, Norcross RD, Knoflach F, Kratzeisen C, Zenner MT, et al. Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3- trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors. Br J Pharmacol 2008; 154: 797-811. (Pubitemid 351821586)
89. Kerr DI, Ong J, Puspawati NM, Prager RH. Arylalkylamines are a novel class of positive allosteric modulators at GABAB receptors in rat neocortex. Eur J Pharmacol 2002; 451: 69-77. (Pubitemid 35246367)
90. Kerr DI, Ong J. Potentiation of metabotropic GABAB receptors by L-amino acids and dipeptides in rat neocortex. Eur J Pharmacol 2003; 468: 103-8. (Pubitemid 36556253)
91. Wise A, Green A, Main MJ, Wilson R, Fraser N, Marshall FH. Calcium sensing properties of the GABAB receptor. Neuropharmacology 1999; 38: 1647-56. (Pubitemid 29430239)
92. Galvez T, Urwyler S, Prezeau L, Mosbacher J, Joly C, Malitschek B, et al. Ca2+ requirement for high-affinity gamma-aminobutyric acid (GABA) binding at GABAB receptors: involvement of serine 269 of the GABABR1 subunit. Mol Pharmacol 2000; 57: 419-26. (Pubitemid 30140870)
93. Brauner-Osborne H, Jensen AA, Sheppard PO, O'Hara P, Krogsgaard-Larsen P. The agonist-binding domain of the calcium-sensing receptor is located at the amino-terminal domain. J Biol Chem 1999; 274: 18382-6.
94. Zhang Z, Qiu W, Quinn SJ, Conigrave AD, Brown EM, Bai M. Three adjacent serines in the extracellular domains of the CaR are required for L-amino acid-mediated potentiation of receptor function. J Biol Chem 2002; 277: 33727-35.
95. Saidak Z, Brazier M, Kamel S, Mentaverri R. Agonists and allosteric modulators of the calcium-sensing receptor and their therapeutic applications. Mol Pharmacol 2009; 76: 1131-44.
96. Silve C, Petrel C, Leroy C, Bruel H, Mallet E, Rognan D, et al. Delineating a Ca2+ binding pocket within the Venus flytrap module of the human calcium-sensing receptor. J Biol Chem 2005; 280: 37917-23.
97. Arey BJ, Seethala R, Ma Z, Fura A, Morin J, Swartz J, et al. A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo. Endocrinology 2005; 146: 2015-22. (Pubitemid 40396912)
98. Fitzpatrick LA, Smith PL, McBride TA, Fries MA, Hossain M, Dabrowski CE, et al. Ronacaleret, a calcium-sensing receptor antagonist, has no significant effect on radial fracture healing time: Results of a randomized, double-blinded, placebo-controlled Phase II clinical trial. Bone 2011; 49: 845-52.